Anne Bruinvels joins EPEMED as executive director
Targeted with growing start-up organisation and building its strategic framework
Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.
‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.
Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.
Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.
You may also like
Finance
![Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network]()
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network
The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Digital
![Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow]()
Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow
The autoloMATE-powered platform connects sample submission, laboratory execution and review into a single digital workflow across Charles River's North American and European Biologics Testing Solutions sites — replacing paper-based processes to accelerate client results
Media
![CPHI Pharma Awards 2026 recognise Touchlight, SeraNovo and Almac among fifteen category winners in Milan]()
CPHI Pharma Awards 2026 recognise Touchlight, SeraNovo and Almac among fifteen category winners in Milan
Touchlight's dbDNA platform took Innovation Catalyst, SeraNovo's NanoGlass oral formulation won Finished Formulation and Almac Clinical Services claimed Supply Chain Excellence — with BMS's Emma Charles named Woman of the Year
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Design & Build
![Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics]()
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Research & Development
![Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine]()
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine
The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif